Website CV Paper
Fields
Finance, Health, Innovation
Job market paper
The Cost of Diversifying R&D
Firms in R&D-intensive industries often take multiple "shots on goal,'' where they invest in several product candidates to increase the likelihood that at least one reaches the market. Leveraging quasi-experimental variation and novel data on pharmaceutical R&D, I show that this diversification is costly. When pharmaceutical firms spread scarce, fixed resources over multiple candidates, they are less likely to successfully develop at least one product. If they do, it takes longer to reach the market. I develop a model of corporate investment in which R&D diversification arises from three mechanisms: complementarity, diminishing marginal returns, and risk preferences. Risk aversion can explain why some firms choose diversification, even when it is productively inefficient. Structural estimation reveals that the majority of firms in my sample invest as if they are risk averse. I provide empirical evidence suggesting that such behavior arises due to principal-agent frictions, like share-price sensitivity. The widespread existence of risk-averse firms has two policy ramifications: current innovation incentives may overcompensate risk-neutral firms for achieving drug approvals, and regulator lenience slows innovation by inducing risk-averse firms towards multiple, weaker drug candidates.